Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Wong, David ^a   Winter, Oliver ^b   Hartig, Christina ^a   Siebels, Svenja ^a   Szyska, Martin ^a   Tiburzy, Benjamin ^a   Meng, Lingzhang ^a   Kulkarni, Upasana ^a   Fähnrich, Anke ^a   Bommert, Kurt ^c   Bargou, Ralf ^c   Berek, Claudia ^d   Chu, Van Trung ^d   Bogen, Bjarne ^e   Jundt, Franziska ^c   Manz, Rudolf Armin ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; INTERLEUKIN 5; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL INTERACTION; CONTROLLED STUDY; EOSINOPHIL; IN VITRO STUDY; IN VIVO STUDY; MEGAKARYOCYTE; MOPC315 CELL LINE; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW; CELL PROLIFERATION; COCULTURE; CYTOLOGY; PATHOLOGY;

MURINAE;

ANIMALS; BONE MARROW; CELL PROLIFERATION; COCULTURE TECHNIQUES; EOSINOPHILS; MEGAKARYOCYTES; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA;

EID: 84907523497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109018     Document Type: Article

References (55)

1. Bataille R, Harousseau J.L. (1997) Multiple myeloma. N Engl J Med 336: 1657-1664.
2. Anderson KC, Carrasco R.D. (2011) Pathogenesis of myeloma. Annu Rev Pathol 6: 249-274.
3. Kuehl WM, Bergsagel P.L. (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2: 175-187.
4. Manz RA, Thiel A, Radbruch A. (1997) Lifetime of plasma cells in the bone marrow. Nature 388: 133-134.
5. Slifka MK, Antia R, Whitmire J.K., Ahmed R. (1998) Humoral immunity due to long-lived plasma cells. Immunity 8: 363-372.
6. Kortuem KM, Stewart A.K. (2013) Carfilzomib. Blood 121: 893-897.
7. Ludwig H, Durie BG, McCarthy P, Palumbo A., San MJ, et al. (2012) IMWG consensus on maintenance therapy in multiple myeloma. Blood 119: 3003-3015.
8. Miguel JS, Weisel K, Moreau P., Lacy M, Song K, et al. (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14: 1055-1066.
9. Moreau P, Richardson PG, Cavo M, Orlowski R.Z., San Miguel JF, et al. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120: 947-959.
10. Palumbo A, Anderson K. (2011) Multiple myeloma. N Engl J Med 364: 1046-1060.
11. Zhu YX, Kortuem KM, Stewart A.K. (2013) Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 54: 683-687.
12. Kuehl WM, Bergsagel P.L. (2012) Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 122: 3456-3463.
13. Edwards CM, Zhuang J, Mundy G.R. (2008) The pathogenesis of the bone disease of multiple myeloma. Bone 42: 1007-1013.
14. Fowler JA, Mundy GR, Lwin S.T., Edwards C.M. (2012) Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res 72: 2183-2189.
15. Moreaux J, Legouffe E, Jourdan E., Quittet P, Reme T, et al. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103: 3148-3157.
16. Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G., Chatterjee, et al. (2004) Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 103: 3511-3515.
17. Honemann D, Chatterjee M, Savino R., Bommert K, Burger R, et al. (2001) The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cellmediated drug resistance of multiple myeloma cells. Int J Cancer 93: 674-680.
18. Bommert K, Bargou RC, Stuhmer T. (2006) Signalling and survival pathways in multiple myeloma. Eur J Cancer 42: 1574-1580.
19. O'Connor BP, Raman VS, Erickson L.D., Cook WJ, Weaver LK, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199: 91-98.
20. Cassese G, Arce S, Hauser A.E., Lehnert K., Moewes B, et al. (2003) Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 171: 1684-1690.
21. Manz RA, Hauser AE, Hiepe F, Radbruch A. (2005) Maintenance of serum antibody levels. Annu Rev Immunol 23: 367-386.
22. Mumtaz IM, Hoyer BF, Panne D, Moser K., Winter O, et al. (2012) Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity. J Autoimmun 39: 180-188.
23. Moser K, Tokoyoda K, Radbruch A., MacLennan I, Manz R.A. (2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 18: 265-270.
24. Winter O, Moser K, Mohr E., Zotos D, Kaminski H, et al. (2010) Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood 116: 1867-1875.
25. Chu VT, Frohlich A, Steinhauser G., Scheel T, Roch T, et al. (2011) Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 12: 151-159.
26. Chu VT, Berek C. (2012) Immunization induces activation of bone marrow eosinophils required for plasma cell survival. Eur J Immunol 42: 130-137.
27. Winter O, Mohr E, Manz R.A. (2011) Alternative cell types form a Multi-Component-Plasma-Cell-Niche. Immunol Lett 141: 145-146.
28. Chu VT, Berek C. (2013) The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev 251: 177-188.
29. Hargreaves DC, Hyman PL, Lu T.T., Ngo VN, Bidgol A, et al. (2001) A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 194: 45-56.
30. Hauser AE, Debes GF, Arce S, Cassese G., Hamann A, et al. (2002) Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol 169: 1277-1282.
31. Tokoyoda K, Egawa T, Sugiyama T., Choi BI, Nagasawa T. (2004) Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20: 707-718.
32. Tokoyoda K, Hauser AE, Nakayama T, Radbruch A. (2010) Organization of immunological memory by bone marrow stroma. Nat Rev Immunol 10: 193-200.
33. Sanz-Rodriguez F, Hidalgo A, Teixido J. (2001) Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 97: 346-351.
34. Moller C, Stromberg T, Juremalm M., Nilsson K, Nilsson G. (2003) Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17: 203-210.
35. Nakayama T, Hieshima K, Izawa D., Tatsumi Y, Kanamaru A, et al.(2003) Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 170: 1136-1140.
36. Alsayed Y, Ngo H, Runnels J., Leleu X, Singha UK, et al. (2007) Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109: 2708-2717.
37. Wong TW, Kita H, Hanson C.A., Walters DK, Arendt BK, et al. (2013) Induction of malignant plasma cell proliferation by eosinophils. PLoS One 8: e70554.
38. Hofgaard PO, Jodal HC, Bommert K, Huard B., Caers J, et al. (2012) A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One 7: e51892.
39. Chatterjee M, Stuhmer T, Herrmann P., Bommert K, Dorken B, et al. (2004) Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 104: 3712-3721.
40. Chu VT, Enghard P, Schurer S., Steinhauser G, Rudolph B, et al. (2009) Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 60: 2083-2093.
41. Gerlo S, Haegeman G, Vanden B.W. (2008) Transcriptional regulation of autocrine IL-6 expression in multiple myeloma cells. Cell Signal 20: 1489-1496.
42. Hov H, Tian E, Holien T., Holt RU, Vatsveen TK, et al. (2009) c-Met signaling promotes IL-6-induced myeloma cell proliferation. Eur J Haematol 82: 277-287.
43. Moreaux J, Sprynski AC, Dillon S.R., Mahtouk K., Jourdan M, et al. (2009) APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 83: 119-129.
44. Quinn J, Glassford J, Percy L., Munson P, Marafioti T, et al. (2011) APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood 117: 890-901.
45. Parsons JC, Coffman RL, Grieve R.B. (1993) Antibody to interleukin 5 prevents blood and tissue eosinophilia but not liver trapping in murine larval toxocariasis. Parasite Immunol 15: 501-508.
46. Corren J (2012) Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med 13: 305-312.
47. Odendahl M, Mei H, Hoyer B.F., Jacobi AM, Hansen A, et al. (2005) Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105: 1614-1621.
48. Oracki SA, Walker JA, Hibbs M.L., Corcoran LM, Tarlinton D.M. (2010) Plasma cell development and survival. Immunol Rev 237: 140-159.
49. Muehlinghaus G, Cigliano L, Huehn S., Peddinghaus A, Leyendeckers H, et al. (2005) Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 105: 3965-3971.
50. Katz BZ (2010) Adhesion molecules-The lifelines of multiple myeloma cells. Semin Cancer Biol 20: 186-195.
51. Jernberg-Wiklund H, Pettersson M, Carlsson M., Nilsson K. (1992) Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia 6: 310-318.
52. Sprynski AC (2009) The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
53. Tagoug I (2011) Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.
54. Molfino NA, Gossage D, Kolbeck R., Parker JM, Geba G.P. (2012) Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 42: 712-737.
55. Schwartz LB, Sheikh J, Singh A. (2010) Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. Curr Med Res Opin 26: 1933-1946.